| Literature DB >> 26469538 |
Abhijit Maji1, Richa Misra1, Anupam Kumar Mondal1,2, Dhirendra Kumar1, Divya Bajaj3, Anshika Singhal1, Gunjan Arora1, Asani Bhaduri1, Andaleeb Sajid1, Sugandha Bhatia1, Sompal Singh4, Harshvardhan Singh4, Vivek Rao1, Debasis Dash1, E Baby Shalini5, Joy Sarojini Michael5, Anil Chaudhary6, Rajesh S Gokhale1, Yogendra Singh1.
Abstract
Extrapulmonary manifestations constitute 15 to 20% of tuberculosis cases, with lymph node tuberculosis (LNTB) as the most common form of infection. However, diagnosis and treatment advances are hindered by lack of understanding of LNTB biology. To identify host response, Mycobacterium tuberculosis infected lymph nodes from LNTB patients were studied by means of transcriptomics and quantitative proteomics analyses. The selected targets obtained by comparative analyses were validated by quantitative PCR and immunohistochemistry. This approach provided expression data for 8,728 transcripts and 102 proteins, differentially regulated in the infected human lymph node. Enhanced inflammation with upregulation of T-helper1-related genes, combined with marked dysregulation of matrix metalloproteinases, indicates tissue damage due to high immunoactivity at infected niche. This expression signature was accompanied by significant upregulation of an immunoregulatory gene, leukotriene A4 hydrolase, at both transcript and protein levels. Comparative transcriptional analyses revealed LNTB-specific perturbations. In contrast to pulmonary TB-associated increase in lipid metabolism, genes involved in fatty-acid metabolism were found to be downregulated in LNTB suggesting differential lipid metabolic signature. This study investigates the tissue molecular signature of LNTB patients for the first time and presents findings that indicate the possible mechanism of disease pathology through dysregulation of inflammatory and tissue-repair processes.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26469538 PMCID: PMC4606593 DOI: 10.1038/srep15214
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Details of LNTB patients enrolled in the study.
| Patient ID | Age | Sex | H/E Staining | Culture | Current medication | History of TB | Microarray | iTRAQ |
|---|---|---|---|---|---|---|---|---|
| E-4 | 13 | F | +ve | +ve | NO | NO | YES | YES |
| E-6 | 12 | M | +ve | +ve | NO | NO | YES | |
| E-7 | 17 | F | +ve | +ve | NO | NO | YES | |
| E-8 | 26 | F | +ve | +ve | NO | NO | YES | YES |
| E-10 | 16 | F | +ve | +ve | NO | NO | YES | YES |
| E-11 | 18 | F | +ve | +ve | NO | NO | YES | |
| E-13 | 26 | F | +ve | +ve | NO | NO | YES | |
| E-14 | 9 | F | +ve | +ve | NO | NO | YES | |
| E-15 | 25 | F | +ve | +ve | NO | NO | YES | |
| E-16 | 13 | F | +ve | +ve | NO | NO | YES | |
| E-17 | 16 | F | +ve | +ve | NO | NO | YES | |
| E-18 | 11 | F | +ve | +ve | NO | NO | YES | |
| E-19 | 15 | F | +ve | +ve | NO | NO | YES |
Figure 1Hematoxylin & eosin staining for identification of granulomatous structures.
Hematoxylin & eosin stained section of patient lymph node infected with M. tuberculosis, showing TB characteristic granuloma with Langhans giant cells at 10×. (A) Granuloma (marked by arrows) and Langhans giant cells (highlighted by arrowheads). (B) Granuloma (marked by arrows) surrounded by lymphoid cells with Langhans giant cell in the centre. (C) Granuloma (marked by arrows) surrounded by lymphoid cells. (D) Granuloma (marked by arrows) and Langhans giant cells (highlighted by arrowheads).
Figure 2Transcriptomic profiling of LNTB infected tissue. (A) Volcano plot showing differentially expressed genes (DEGs) in microarray analysis of LNTB infected tissue with respect to control tissue. The negative log10 transformed false discovery rate (FDR) adjusted p-values are plotted against the average log2 fold changes in expression (x axis). DEGs were determined using limma followed by FDR correction. Horizontal dashed line indicates the threshold for significance (FDR adjusted P < 0.05) and vertical dashed line indicates the upregulated (right side) and downregulated (left side) probes. (B,C) Functional enrichment analyses of top 10 percent downregulated (B) and upregulated (C) DEGs in DAVID. The bar graph shows the number of DEGs observed in each gene ontology (GO) category (atleast 20 genes per category), corresponding p-values are represented in the secondary axis.
Figure 3Proteomic profiling of LNTB infected tissue.
(A) Functional enrichment analyses of differentially expressed proteins generated using DAVID. The bar graph displays the number of overexpressed proteins observed in each GO category. All the categories presented in the graph have P-values < 0.05. (B) Heat map showing gene expression status of significantly variant proteins in proteomic profiling of LNTB tissue. Blue = low expression, red = high expression.
Figure 4Qualitative heat map analysis of Th1/Th2 pathway genes in LNTB, PTB and TBM.
Heat map of the expression of genes belonging to the Th1 and Th2 subset, (subset mentioned in Qiagen SABiosciences online resource). Microarray datasets of current study (LNTB), PTB (GSE20050) and TBM (GSE23074) were considered for this analysis. The results presented represent the differential gene expression status in the disease in relation to the controls chosen in respective studies. Unsupervised hierarchical clustering was performed. Upregulated genes are marked by the red boxes; downregulated genes by blue boxes and yellow boxes indicate lack of differential expression.
Figure 5Validation of selected targets by Quantitative real time PCR and Immunohistochemistry.
(A) Quantitative real time PCR of VATB2, FASN, IFN, LTA4H, MMP9, PSME2, TIMP2 and TNF mRNA levels. All fold changes were derived using the formula, 2−(ΔΔCP), and patient IDs are indicated in adjoining box. Statistical significance of log2 fold change as determined using one sample t-test is shown on the top of each boxplot by “*” for p-value < 0.05, “**” for p-value < 0.001. (B) Immunohistochemical analysis of lymph node sections from LNTB patients and healthy controls. Staining was performed with anti-LTA4H, anti-PSME2 and anti-VATB2 antibodies followed by colorimetric detection. Positive staining (brown; diaminobenzidine staining) and negative staining (blue; nuclear hematoxylin staining) are shown. Negative control was included without primary antibody incubation. Magnification: 40×